This July 2020 photo provided by Johnson & Johnson shows a vial of the COVID-19 vaccine in Belgium. The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday, Feb. 27, 2021 cleared a Johnson & Johnson shot that works with just one dose instead of two.(Courtesy Photo / Johnson & Johnson)

This July 2020 photo provided by Johnson & Johnson shows a vial of the COVID-19 vaccine in Belgium. The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday, Feb. 27, 2021 cleared a Johnson & Johnson shot that works with just one dose instead of two.(Courtesy Photo / Johnson & Johnson)

1-dose shot cleared, giving US its 3rd COVID-19 vaccine

The FDA cleared it Saturday.

By LAURAN NEERGAARD and MATTHEW PERRONE

Associated Press

WASHINGTON — The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of two.

Health experts are anxiously awaiting a one-and-done option to help speed vaccinations, as they race against a virus that already has killed more than 510,000 people in the U.S. and is mutating in increasingly worrisome ways.

The FDA said J&J’s vaccine offers strong protection against what matters most: serious illness, hospitalizations and death. One dose was 85% protective against the most severe COVID-19 illness, in a massive study that spanned three continents — protection that remained strong even in countries such as South Africa, where the variants of most concern are spreading.

“This is really good news,” Dr. Francis Collins, director of the National Institutes of Health, told The Associated Press Saturday. “The most important thing we can do right now is to get as many shots in as many arms as we can.”

Shipments of a few million doses to be divided among states could begin as early as Monday. By the end of March, J&J has said it expects to deliver 20 million doses to the U.S., and 100 million by summer.

[Over 100K vaccine doses heading to Alaska in March]

J&J also is seeking authorization for emergency use of its vaccine in Europe and from the World Health Organization. Worldwide, the company aims to produce about 1 billion doses globally by the end of the year. On Thursday, the island nation of Bahrain became the first to clear its use.

On Sunday, a U.S. advisory committee will meet to recommend how to prioritize use of the single-dose vaccine. And one big challenge is what the public wants to know: Which kind of vaccine is better?

“In this environment, whatever you can get — get,” said Dr. Arnold Monto of the University of Michigan, who chaired an FDA advisory panel that unanimously voted Friday that the vaccine’s benefits outweigh its risks.

Data is mixed on how well all the vaccines being used around the world work, prompting reports in some countries of people refusing one kind to wait for another.

In the U.S., the two-dose Pfizer and Moderna shots were 95% protective against symptomatic COVID-19. J&J’s one-dose effectiveness of 85% against severe COVID-19 dropped to 66% when moderate cases were rolled in. But there’s no apples-to-apples comparison because of differences in when and where each company conducted its studies, with the Pfizer and Moderna research finished before concerning variants began spreading.

NIH’s Collins said the evidence of effectiveness shows no reason to favor one vaccine over another.

“What people I think are mostly interested in is, is it going to keep me from getting really sick?” said NIH’s Collins. “Will it keep me from dying from this terrible disease? The good news is all of these say yes to that.”

Also, J&J is testing two doses of its vaccine in a separate large study. Collins said if a second dose eventually is deemed better, people who got one earlier would be offered another.

The FDA cautioned that it’s too early to tell if someone who gets a mild or asymptomatic infection despite vaccination still could spread the virus.

There are clear advantages aside from the convenience of one shot. Local health officials are looking to use the J&J option in mobile vaccination clinics, homeless shelters, even with sailors who are spending months on fishing vessels — communities where it’s hard to be sure someone will come back in three to four weeks for a second vaccination.

The J&J vaccine also is easier to handle, lasting three months in the refrigerator compared to the Pfizer and Moderna options, which must be frozen.

“We’re chomping at the bit to get more supply. That’s the limiting factor for us right now,” said Dr. Matt Anderson of UW Health in Madison, Wisconsin, where staffers were readying electronic health records, staffing and vaccine storage in anticipation of offering J&J shots soon.

The FDA said studies detected no serious side effects. Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache.

The FDA said there is “a remote chance” that people may experience a severe allergic reaction to the shot, a rare risk seen with the Pfizer and Moderna vaccines.

The vaccine has been authorized for emergency use in adults 18 and older for now. But like other vaccine makers, J&J is about to begin a study of its vaccine in teens before moving to younger children later in the year, and also plans a study in pregnant women.

All COVID-19 vaccines train the body to recognize the new coronavirus, usually by spotting the spikey protein that coats it. But they’re made in very different ways.

J&J’s shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along. It’s the same technology the company used in making an Ebola vaccine, and similar to COVID-19 vaccines made by AstraZeneca and China’s CanSino Biologics.

The Pfizer and Moderna vaccines are made with a different technology, a piece of genetic code called messenger RNA that spurs cells to make those harmless spike copies.

The AstraZeneca vaccine, already used in Britain and numerous other countries, is finishing a large U.S. study needed for FDA clearance. Also in the pipeline, Novavax uses a still different technology, made with lab-grown copies of the spike protein, and has reported preliminary findings from a British study suggesting strong protection.

Still other countries are using “inactivated vaccines,” made with killed coronavirus by Chinese companies Sinovac and Sinopharm.

More in News

(Juneau Empire File)
Aurora forecast for the week of Nov. 27

These forecasts are courtesy of the University of Alaska Fairbanks’ Geophysical Institute… Continue reading

Angie Flick (center), finance director for the City and Borough of Juneau, provides details of an early draft of next year’s municipal budget to Assembly members as City Manager Katie Koester (left) and Budget Manager Adrien Wendel listen during a Finance Committee meeting Wednesday night in the Assembly Chambers. (Mark Sabbatini / Juneau Empire)
Assembly members prepare to retreat so they can move ahead on next year’s budget

“Very draft” $190 million spending plan for FY25 based on status quo has $1 million deficit.

(Michael Penn / Juneau Empire File)
Police calls for Monday, Nov. 27, 2023

This report contains public information from law enforcement and public safety agencies.

The front page of the Juneau Empire on Nov. 30, 2005. (Photo by Mark Sabbatini / Juneau Empire)
Empire Archives: Juneau’s history for the week of Dec. 3

Three decades of capital city coverage.

Cheyenne Latu (left), a pharmacy technician at Ron’s Apothecary Shoppe, and business co-owner Gretchen Watts hang a poster at the front counter Thursday announcing the store’s closure after Dec. 6 as Jessica Kirtley, another pharmacy technician, works at the front register. The nearby Safeway supermarket has agreed to take the prescriptions of all customers as well as hire all of the independent pharmacy’s employees, according to the co-owners who are retiring. (Mark Sabbatini / Juneau Empire)
Ron’s Apothecary Shoppe closing after nearly 50 years as co-owners retire; last day is Dec. 6

Safeway taking over all prescriptions and offering jobs to all employees, according to owners.

Attendees at the Friends of NRA — Juneau’s banquet in 2019 talk near auction tables at Centennial Hall. The fundraising event is resuming Saturday after a four-year COVID-19 disruption. (Photo courtesy of Friends of NRA — Juneau)
Friends of NRA — Juneau fundraising banquet returns Saturday after four-year pandemic absence

New Zealand hunting safari, signed Ted Nugent guitar among items being offered.

Wade Bryson, a Juneau Assembly member, explains why he favors giving local businesses a “sales tax holiday” for at least one day next year, targeting Feb. 29 as a suitable date, during the Assembly’s Finance Committee meeting Wednesday night. The committee voted to hold onto the proposal for further study rather than sending it to the full Assembly. (Mark Sabbatini / Juneau Empire)
A local sales tax holiday? Don’t pack your shopping bags yet

Proposal to waive taxes for a day or two each year isn’t a quick sale to most Assembly members

(Michael Penn / Juneau Empire file photo)
Police calls for Tuesday, Nov. 28, 2023

This report contains public information from law enforcement and public safety agencies.

Choir members rehearse Tuesday night for a Bach holiday concert at Ḵunéix̱ Hídi Northern Light United Church. (Mark Sabbatini / Juneau Empire)
Quartet of Bach compositions joins lineup of local large-ensemble performances this season

Concerts this weekend part of resurging “wealth of riches” by choruses and orchestras, director says.

Most Read